rhPSMA-7.3 (18F) Injection

DRUG3 trials

Sponsors

Blue Earth Diagnostics

Conditions

Prostate Cancer

Phase 1

Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer

CompletedNCT03995888

Blue Earth DiagnosticsProstate Cancer

Start: 2019-06-11End: 2020-04-16Updated: 2026-02-12

Phase 3

Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence

CompletedNCT04186845

Blue Earth DiagnosticsProstate Cancer

Start: 2020-05-04End: 2021-04-28Updated: 2025-09-22

Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.

CompletedNCT04186819

Blue Earth DiagnosticsProstate Cancer

Start: 2020-03-02End: 2021-06-21Updated: 2025-02-26

Related Papers

How Standard of Truth Methodology Impacts Diagnostic PSMA-Targeting Radiopharmaceutical Evaluation: Learnings from the Phase 3 SPOTLIGHT Study

Diagnostics2025-02-141 citations

<sup>18</sup>F-Flotufolastat Positron Emission Tomography in African American Patients With Suspected Prostate Cancer Recurrence: Findings From the Phase 3 SPOTLIGHT Study.

2024-07-141 citations

True-Positive<sup>18</sup>F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study

Journal of Nuclear Medicine2024-05-234 citations

Impact of standard-of-truth method on evaluation of a diagnostic PET radiopharmaceutical: Learnings from the phase 3 SPOTLIGHT study.

Journal of Clinical Oncology2024-01-291 citations

Impact of <sup>18</sup>F-flotufolastat PET on management of patients with recurrent prostate cancer: Data from the SPOTLIGHT study.

Journal of Clinical Oncology2024-01-29

Quantitative and Qualitative Assessment of Urinary Activity of <sup>18</sup>F-Flotufolastat-PET/CT in Patients with Prostate Cancer: a Post Hoc Analysis of the LIGHTHOUSE and SPOTLIGHT Studies.

2023-11-0610 citations

Diagnostic Performance and Safety of Positron Emission Tomography with <sup>18</sup>F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE).

2023-07-0564 citations

Diagnostic Performance and Safety of <sup>18</sup>F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT).

2023-04-2646 citations

MP40-13 <sup>18</sup> F-RHPSMA-7.3 DETECTION RATES IN PATIENTS WITH RECURRENCE OF PROSTATE CANCER FOLLOWING PRIMARY TREATMENT WITH RADIATION THERAPY: RESULTS FROM THE SPOTLIGHT STUDY

The Journal of Urology2023-03-23

Detection of true positive M1 lesions by <sup>18</sup>F-rhPSMA-7.3 PET in newly diagnosed prostate cancer: Results from the phase 3 prospective LIGHTHOUSE study.

Journal of Clinical Oncology2023-02-203 citations

PLLBA-02 IMPACT OF <sup>18</sup> F-RHPSMA-7.3 PET ON UPSTAGING OF PATIENTS WITH PROSTATE CANCER RECURRENCE: RESULTS FROM THE PROSPECTIVE, PHASE 3, MULTICENTER, SPOTLIGHT STUDY

The Journal of Urology2022-04-071 citations

Detection rate of <sup>18</sup>F-rhPSMA-7.3 PET in patients with suspected prostate cancer recurrence: Results from a phase 3, prospective, multicenter study (SPOTLIGHT)

Journal of Clinical Oncology2022-02-166 citations

Kinetic analysis and optimisation of <sup>18</sup>F-rhPSMA-7.3 PET imaging of prostate cancer.

2021-04-1213 citations